

DOTATATE acetate

Chemical Properties

CAS No. : 177943-89-4

Formula: C67H94N14O21S2


Molecular Weight: 1495.69

Storage:

Keep away from moisture, Store under nitrogen, Keep away from direct sunlight

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	DOTATATE acetate is a DOTA-binding peptide, a growth inhibitor analog, and a novel PET tracer involved in the assessment of functional imaging of highly differentiated neuroendocrine tumors (NETs).
Targets(IC50)	Others
In vivo	Dotatate acetate exhibits high affinity and specificity, allowing it to bind to and activate the somatostatin receptor subtype 2 (SSTR2) effectively, thereby inhibiting tumor cell proliferation and differentiation[1].

Solubility Information

Solubility	H2O: 5.00 mg/mL (3.34 mM), Sonication is recommended. DMSO: 45 mg/mL (30.09 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: 4.5 mg/mL (3.01 mM), Solution. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.6686 mL	3.3429 mL	6.6859 mL
5 mM	0.1337 mL	0.6686 mL	1.3372 mL
10 mM	0.0669 mL	0.3343 mL	0.6686 mL
50 mM	0.0134 mL	0.0669 mL	0.1337 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Jong M, et al. Combination radionuclide therapy using ¹⁷⁷Lu- and ⁹⁰Y-labeled somatostatin analogs. J Nucl Med. 2005 Jan;46 Suppl 1:13S-7S.

Gains JE, et al. ⁶⁸Ga-DOTATATE and ¹²³I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. Nucl Med Commun. 2020 Aug 10.

Breeman WAP, et al. Optimising conditions for radiolabelling of DOTA-peptides with ⁹⁰Y, ¹¹¹In and ¹⁷⁷Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):917-20.

Reubi JC, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000 Mar;27(3):273-82.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481